Overview of the study cohort. (A) Schematic overview of multiomics data obtained from our cohort. TES and WES were performed on 362 and 11 AML samples, respectively. The analysis focuses on 35 genes that are most frequently mutated in AML. (B) Venn diagram depicting the number of samples within each data layer. (C) The French-American-British (FAB) subtyping, WHO classification, and multiomics information of 374 patients with AML. (D) The proportion of WHO-defined entities in different age groups. All patients were categorized into 3 age groups, namely, 15 to 44 years, 45 to 59 years, and 60 to 80 years. (E-F) UMAP of AML samples using 10 016 measured proteins (E) and 39 348 measured phosphosites (F), with colors denoting different WHO subtypes. (G) Gene set variation analysis scores for proteomics based on differentially regulated gene ontology (GO) pathways in WHO subtypes (left heat map). Spearman correlation coefficients of the proteome and the transcriptome for the annotated pathways are displayed (right heat map, asterisks mark significantly correlated pathways with P < .05, Benjamini-Hochberg-corrected). (H) Heat map depicting kinome profiling with z scores calculated by kinase-substrate enrichment analysis algorithm. GSVA, gene set variation analysis; NOS, not otherwise specified; RNA-seq, RNA sequencing; TES, targeted exome sequencing; WES, whole exome sequencing.